Our findings warrant further investigation of JQ1 or OTX015 as a sensitizer of TRAIL/DR-targeted cancer therapy in vivo and in the clinic, thus promising the clinical translational significance of this approach. The gene discussed is TNFSF10; the disease is cancer.